Dr Yongchuan Gu


Dr Gu obtained BPharmSci in Medicinal Chemistry in 1993 and MSc in Pharmacology in 2002. He was invited to University of Otago as a visiting Research Fellow in 2002 to carry out preclinical development of a mitochondria-targeted antioxidant at School of Pharmacy. He gained experience on GLP operation / documentation at ZenithTechnology Ltd, a NZ-based bioanalytical & pharmacokinetic specialty CRO, where he acted as a Senior Scientist in charge of method development / validations for a variety of drugs. He conferred his PhD from University of Auckland in 2010 and finished postdoc training in Auckland Cancer Society Research Centre where he was responsible for preclinical development for different drug discovery programs targeting tumour hypoxia. His current research interest is developing targeted proteomics technology as a powerful tool to probe potential biomarkers of HAPs with the goal of identifying patients that will be responsive to the therapy. He was recognised with receipt of the 2013 Keith & Meida Hepburn Young Scientist of the Year Award by the Cancer Society Auckland for his contribution to anti-cancer drug development in NZ.

Teaching | Current

Drugs and Society (P111G)
PostGrad course -Pharmaceutical Quality Assurance (P752)


Li Family Cancer Research Fellowship (2016)
AAHA Collaborative Research Grant (2015)
AMRF project grant (2014)
HRC Programme (2014)
Marsden Fund (2013)
Keith & Meida Hepburn Young Scientist of the Year (2013)
NZ-China Scientist Exchange Programme (2013)
Genesis Oncology Research Grant (2011)
Technology for Industry Fellowships (2006)

Committees/Professional groups/Services

American Association for Cancer Research; American Society for Pharmacology and Experimental Therapeutics; American Association of Pharmaceutical Scientists; Auckland Cancer Research Network; Maurice Wilkins Centre

Selected publications and creative works (Research Outputs)

  • Gu, Y., Chang, T. T.-A., Wang, J., Jaiswal, J. K., Edwards, D., Downes, N. J., ... Hickey, A. J. R. (2017). Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice. Frontiers in pharmacology, 810.3389/fphar.2017.00531
    Other University of Auckland co-authors: Tony Hickey, Jagdish Jaiswal, Frederik Pruijn, Michael Hay, William Wilson, Kevin Hicks
  • Cao, J., Wang, Y., Dong, R., Lin, G., Zhang, N., Wang, J., ... Ying, M. (2015). Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer research, 75 (22), 4839-4851. 10.1158/0008-5472.can-15-0711
  • Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., ... Goldstein, D. P. (2015). Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer research, 75 (19), 4211-4223. 10.1158/0008-5472.can-15-1107
    Other University of Auckland co-authors: Francis Hunter, William Wilson
  • Konopleva, M., Thall, P. F., Yi, C. A., Borthakur, G., Coveler, A., Bueso-Ramos, C., ... Ravandi, F. (2015). Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 100 (7), 927-934. 10.3324/haematol.2014.118455
    Other University of Auckland co-authors: William Wilson
  • Sheng, R., Li, S., Lin, G., Shangguan, S., Gu, Y., Qiu, N., ... Hu, Y. (2015). Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives. RSC Adv, 5 (100), 81817-81830. 10.1039/C5RA15191K
  • Abbattista, M. R., Jamieson, S. M. F., Gu, Y., Nickel, J. E., Pullen, S. M., Patterson, A. V., ... Guise, C. P. (2015). Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer biology & therapy, 16 (4), 610-622. 10.1080/15384047.2015.1017171
    Other University of Auckland co-authors: Adam Patterson, Christopher Guise, Maria Abbattista, William Wilson, Stephen Jamieson, Susan Pullen
  • Gu, Y., Jaiswal, J. K., Wang, J., Hicks, K. O., Hay, M. P., & Wilson, W. R. (2014). Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution. Journal of pharmaceutical sciences, 103 (11), 3464-3472. 10.1002/jps.24099
    Other University of Auckland co-authors: Michael Hay, William Wilson, Kevin Hicks, Jagdish Jaiswal
  • Hunter, F. W., Jaiswal, J. K., Hurley, D. G., Liyanage, H. D. S., McManaway, S. P., Gu, Y., ... Print, C. G. (2014). The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs. Biochemical Pharmacology, 89 (2), 224-235. 10.1016/j.bcp.2014.03.001
    Other University of Auckland co-authors: Jagdish Jaiswal, William Wilson, Frederik Pruijn, Moana Tercel, Cristin Print, Francis Hunter, Sarah McManaway

Contact details

Primary location

M&HS BUILDING 504 - Bldg 504
Level B, Room B01A
New Zealand

Social links